Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Taxane-containing chemotherapy regimens

Acknowledgements

Membership of NBOCC* taxanes subgroup

This guideline was developed by a multidisciplinary working group convened by NBOCC*

Dr Craig Lewis Medical Oncologist (Chair)
Dr Alison Davis Medical Oncologist
Dr Tom Ferguson Medical Oncology Advanced Trainee
Dr James French Surgeon
Ms Judy Iasiello Breast Care Nurse
Ms Elisabeth Kochman Consumer Representative
Dr Anna Nowak Medical Oncologist

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Membership of NBOCC* Early Breast Cancer Working Group

The development of this guideline was overseen by a multidisciplinary working group convened by NBOCC*: Dr Karen Luxford (Facilitator), Associate Professor Michael Bilous, Ms Elizabeth Kochman, Mr James Kollias, Dr Craig Lewis, Dr Jonathon Osborne, Dr Sue Pendlebury, Ms Leanne Pentland, Associate Professor Kelly-Anne Phillips, Ms Sue Rovelli, Dr Jane Turner

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

NBOCC* staff

Ms Heidi Wilcoxon Senior Project Officer (Project lead)
Ms Katrina Anderson Project Officer—Research
Dr Karen Luxford General Manager
Ms Alison Pearce Program Manager
Ms Rosemary Vagg Senior Project Officer—Research

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

External review

NBOCC* acknowledges those who gave their time to provide comment on the draft guideline recommendations as part of the external review process

Full details of adjuvant trial results are provided in the Cochrane review Taxanes for adjuvant treatment of early breast cancer2, which can be accessed via the Cochrane Library website: www.cochrane.org

Full details of neoadjunvant trial results are provided in the document Taxanes for neoadjuvant treatment of early breast cancer: a systematic review3, which can be accessed via the NBOCC* website: www.nbocc.org.au

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Pharmaceutical Benefits Scheme listing for taxanes; paclitaxel and docetaxel

As of September 2007. For updates after this date go to http://www.pbs.gov.au

Paclitaxel and docetaxel are currently subsidised for the following indications in the treatment of early breast cancer:

  • Paclitaxel – adjuvant treatment of node-positive breast cancer administered sequentially to an anthracycline and cyclophosphamide
  • Docetaxel – adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide
  • Paclitaxel and docetaxel – treatment of HER2 positive early breast cancer in combination with trastuzumab

Development process

Priority topic areas for NBOCC* guideline development are determined in consultation with key stakeholders including experts in relevant disciplines and consumer representatives. A specific multidisciplinary Working Group, including consumers, is established for each topic identified and is involved in all aspects of guideline development. A systematic evidence review is undertaken for each guideline. All members are asked to declare any conflicts of interest and these declarations are recorded.  The content of the guideline is not influenced by any external funding body. The guideline is reviewed externally by key stakeholders and the wider community and endorsement is sought from relevant professional colleges and groups in Australia.

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.


Recommendations for use of taxane-containing chemotherapy regimens for the treatment of early (operable) breast cancer was prepared and produced by:

National Breast and Ovarian Cancer Centre*
Level 1, Suite 103, 355 Crown Street Surry Hills NSW 2010
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 Frecall 1800 624 973
Website: www.nbocc.org.au

© Cancer Australia 2011
ISBN Print: 978-1-74127-116-4 Online: 978-1-74127-117-1 CIP : 13617

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from National Breast and Ovarian Cancer Centre*. Requests and enquiries concerning reproduction and rights should be addressed to the Corporate Communications Manager, National Breast and Ovarian Cancer Centre*.

Recommended citation
National Breast and Ovarian Cancer Centre*. Recommendations for use of taxane-containing chemotherapy regimens for the treatment of early (operable) breast cancer. National Breast and Ovarian Cancer Centre*, Surry Hills, NSW, 2010.

Disclaimer
National Breast and Ovarian Cancer Centre* does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. National Breast and Ovarian Cancer Centre* develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.

National Breast and Ovarian Cancer Centre* is funded by the Australian Government Department of Health and Ageing.

* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.

Published using CeCC Docbook Manager